Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study | Journal of Clinical Oncology
PURPOSEPatients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas, with …Fixed-duration glofitamab achieves high and durable CR rates with manageable safety in R/R MCL.